Elan Corporation PLC To Sell Rights To Prialt In Europe To Eisai Company, Ltd.; Elan May Receive Up To $100 Million
DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 9, 2006--Elan Corporation, plc today announced that it has agreed to sell the rights to Prialt(TM) (ziconotide, non-opioid severe chronic pain agent) in Europe to Eisai Co., Ltd (Eisai), while retaining the product rights in the United States.